aLF Reader and ImplantSafeDR test detects aMMP8 enzyme that causes peri-implantitis accurately and early
Solingen-based Dentognostics GmbH has announced today (7th November 2017) that it has entered a partnership with QIAGEN Lake Constance that enables users of the new QIAGEN aLF Reader diagnostic device partnered with its ImplantSafeDR® to improve detection of the inflammation processes that damage dental implants. The new system recognises subclinical inflammation processes in their earliest stages thanks to the quantitative assessment of the collagen-destroying enzyme aMMP8.
Measurement by QIAGEN's aLF reader is made using the ImplantSafeDR Immuno-Assay, part of Dentognostics’ innovative aMMP8 “lab-on-a-chip” technology. The test is performed chairside directly on the patient, is completely painless, takes only 30 seconds, and is completely sterile. It was developed in partnership with Professor Timo Sorsa and his research group at the University of Helsinki to protect patients from dental implant failure by detecting damaging inflammation early enough for effective treatment.
Dirk-Rolf Gieselmann, Chairman of the Dentognostic Group explained: “Dentognostics is excited to be bringing our ImplantSafeDR test, an aMMP8-based assay, to market exclusively with QIAGEN's aLF Reader. QIAGEN's technical and market expertise make it an ideal partner for Dentognostics. We look forward to expanding the product’s reach through our partnership.”
Michael Doumanas, Head of Sales and Marketing for QIAGEN Point-of-Need Systems, agrees: “QIAGEN is delighted to team with Dentognostics to bring its dental ImplantSafeDR immunoassay and our aLF lateral flow reader to dentists and their patients across the EU.
“Together, the ImplantSafeDR test and aLF reader enable dentists to detect peri-implantitis in its earliest stages to better protect dental implants. We look forward to working with Dentognostics to bring this important new technology to market, which will directly benefit dentists and their patients.”
The new test supplements clinical diagnosis such as the periodontal screening index (PSI)/bleeding on probing (BOP) by identifying important immunological elements of subclinical collagen breakdown, which are not detectable in their early stages using x-ray or probing. The sensitivity of the new method is between 75-95%, up to three times more sensitive than BOP.
Nearly 50% of dental implants show signs of peri-implant inflammation. As a result, patients with implants have a 10-fold increased risk of peri-implantitis leading to implant loss. For example, in Germany alone approximately four million affected implant patients will see the effective life-span implant supported restoration improved thanks to the Dentognostics’ test used with QIAGEN’s reader; which has already been applied in various versions to a broad range of molecular and other point of need tests. Thousands of the units are now in use.
The new technology will be presented at MEDICA 2017 (Hall 3, booth E84) from 13th to 16th November in Düsseldorf.